Oculis Holding AG
OCSDrugs in Pipeline
7
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Aug 20, 2026
24dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How OCS's past catalysts played out
Dexamethasone ophthalmic suspension (OCS-01)
Diabetic Macular Edema
licaminlimab
Dry Eye Disease
Privosegtor
Optic Neuritis
OCS-01
Inflammation Eye Pain
Dexamethasone nanoparticles eye drops
Diabetic Macular Edema
OCS-05 +SoC (corticosteroid) IV administration
Optic Neuritis
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
Inflammation Corneal
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dexamethasone ophthalmic suspension (OCS-01) | Phase 3 | Diabetic Macular Edema | - | - |
licaminlimab | Phase 3 | Dry Eye Disease | - | - |
Privosegtor | Phase 3 | Optic Neuritis | - | - |
OCS-01 | Phase 3 | Inflammation Eye Pain | - | - |
Dexamethasone nanoparticles eye drops | Phase 2 | Diabetic Macular Edema | - | - |
OCS-05 +SoC (corticosteroid) IV administration | Phase 2 | Optic Neuritis | - | - |
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL | Phase 2 | Inflammation Corneal | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Oculis Holding AG's drug pipeline?→
CatalystAlert tracks 7 drug candidates in Oculis Holding AG's (OCS) pipeline across Phase 3, Phase 2. Its lead program is Dexamethasone ophthalmic suspension (OCS-01) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oculis Holding AG's next FDA catalyst?→
Oculis Holding AG's (OCS) next tracked catalyst is a Earnings expected August 20, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OCS biotech catalysts?→
Add OCS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oculis Holding AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.